24,483 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,483 shares of the biotechnology company’s stock, valued at approximately $2,035,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC boosted its stake in shares of Corcept Therapeutics by 96.1% in the 3rd quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock worth $39,615,000 after buying an additional 248,362 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in Corcept Therapeutics in the third quarter worth $56,000. Allspring Global Investments Holdings LLC boosted its position in Corcept Therapeutics by 11.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 239,812 shares of the biotechnology company’s stock worth $20,204,000 after purchasing an additional 25,206 shares during the last quarter. Merit Financial Group LLC grew its stake in Corcept Therapeutics by 36.1% in the 3rd quarter. Merit Financial Group LLC now owns 3,808 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 1,011 shares during the period. Finally, Abacus FCF Advisors LLC purchased a new stake in shares of Corcept Therapeutics during the 3rd quarter valued at $3,238,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Buying and Selling

In related news, CEO Joseph K. Belanoff sold 40,000 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the sale, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the transaction, the insider directly owned 7,904 shares of the company’s stock, valued at $628,526.08. The trade was a 71.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 196,700 shares of company stock valued at $15,474,198. 20.50% of the stock is owned by company insiders.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $38.20 on Monday. The firm’s 50 day moving average is $76.45 and its 200 day moving average is $74.83. The stock has a market capitalization of $4.02 billion, a P/E ratio of 43.41 and a beta of 0.23. Corcept Therapeutics Incorporated has a 12 month low of $32.99 and a 12 month high of $117.33. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The business had revenue of $207.64 million during the quarter, compared to analysts’ expectations of $223.78 million. During the same quarter in the prior year, the firm posted $0.41 earnings per share. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. On average, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. UBS Group initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price on the stock. HC Wainwright reduced their target price on shares of Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating for the company in a research report on Friday. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 15th. Finally, Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $80.83.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord cut its price target from $140 to $99 but kept a “buy” rating, signaling some sell‑side conviction that there is still meaningful upside from current levels if the company resolves regulatory issues or demonstrates efficacy in follow‑up data. Benzinga
• Neutral Sentiment: Options implied volatility has surged, reflecting elevated uncertainty and trader interest; that can amplify price moves (both rebounds and further declines) and is likely contributing to today’s bounce as short squeezes / gamma flows unwind. Implied Volatility Surging for Corcept Stock Options
• Neutral Sentiment: Unusually large options trading was reported around CORT, consistent with the volatility spike; that activity can produce sharp intraday rallies even when fundamentals remain unchanged. Monitor open interest and large‑block trades for clues to whether the move is technical/speculative versus a change in fundamentals. Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)
• Negative Sentiment: The FDA issued a Complete Response Letter for relacorilant, saying the agency needs additional evidence of effectiveness for treating hypercortisolism (Cushing’s). That CRL drove the prior ~50%+ collapse in the share price and is the core fundamental headwind — approval now requires more data or discussions with the FDA that could delay or derail the drug’s U.S. launch. Corcept Receives Complete Response Letter for Relacorilant
• Negative Sentiment: Multiple outlets summarize the practical impact: analysts and investors marked down valuations and the stock hit new lows after the FDA decision — this is an ongoing risk to revenue/cash‑flow forecasts if relacorilant was a key growth driver. Corcept Tanks on FDA’s CRL to Relacorilant NDA in Hypercortisolism
• Negative Sentiment: Kaplan Fox has alerted investors to a possible securities‑law investigation into Corcept, which can prolong downside pressure and raise potential legal/settlement expenses. This increases headline risk even if operational issues are later resolved. Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.